We retrospectively collect the metastatic gastric cancer patients who received a surgical resection of both primary diseases and metastatic lesions during January 2006 and December 2012. c-MET protein expression and amplification are assessed in paraffin-embedded tissues of the primary and metastatic diseases obtained from 100 patients by immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH). In order to compare c-Met expression and amplification between early and advanced stage, we will match 100 early stage (stage I and stage II) patients. MET IHC will employ the Dako MET IHC assay and supplied assay protocol and pathology scoring guideline.